CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...